The proportion of Cushing’s syndrome patients whose disease is caused by a tumor in the adrenal glands is higher…
Articles by Inês Martins, PhD
Isturisa (osilodrostat), an approved therapy for Cushing’s disease, continues to demonstrate high and sustained responses in patients for whom …
The Phase 3 GRACE clinical trial evaluating Corcept Therapeutics‘ relacorilant as a potential treatment for high blood…
One year of treatment with under-the-skin Signifor (pasireotide) lessens tumor volume in many Cushing’s disease patients for…
Blocking the EGFR signaling pathway using the breast cancer treatment lapatinib significantly reduces the amount of adrenocorticotropic hormone (ACTH)…
A shorter duration of adrenal insufficiency — when the adrenal gland is not working properly — after surgical removal of…
Signifor (pasireotide) — a treatment approved for Cushing’s disease patients who are not cured by surgery — reduces the…
Cushing’s disease patients whose pituitary tumors carry a USP8 mutation are more likely to achieve remission after surgery than those…
Cushing’s syndrome patients deemed in biological remission are rarely functionally cured, continuing to report low quality of life scores,…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to fluasterone (ST-002) for the treatment of nonalcoholic fatty liver disease,…